Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Gets $2M Loan

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems has entered into a $2 million loan agreement with Oxford Finance Corp., the Fremont, Calif.-based firm disclosed in a filing with the US Securities and Exchange Commission today.

The agreement was effective Dec. 7, pursuant to a secured promissory note. The note will accrue at a fixed rate of roughly 13 percent.

In connection with the loan, WaferGen issued to Oxford a warrant to purchase 95,368 of the firm's common stock. The warrant is exercisable immediately at a price of $1.468 per share and expires in five years.

WaferGen's stock closed at $1.27 in Monday trade on the OTC Bulletin Board.

The firm said that it intends to use the loan for general corporate purposes.

Last month, WaferGen reported third-quarter revenues of $633,000, as a result of the summer launch of its SmartChip Real-Time PCR System. The firm finished its quarter ended Sept. 30, with $4.4 million in cash and cash equivalents.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.